Eli Lilly Stock News

Eli Lilly's tirzepatide aced a pair of clinical trials. The medicine's sales potential looks mouthwatering.

Healthcare stocks can offer investors more predictable growth opportunities than artificial intelligence, where there's much more uncertainty in the long run. Eli Lilly and Novo Nordisk have top drugs

Eli Lilly is the developer of GLP-1 treatments Mounjaro and Zepbound. Currently used to treat diabetes and obesity, they could have far more reach.

AbbVie is an unstoppable passive income machine. Eli Lilly offers a sizzling stock performance and a growing dividend.

Eli Lilly (LLY) reports earnings before the bell Tuesday, with investors and analysts watching to see how much weight-loss drugs are continuing to drive the company's growth.

Eli Lilly stock (NYSE: LLY) will report its Q1 results on Tuesday, April 30. The pharmaceutical giant is expected to garner $8.9 billion in sales and $2.46 in adjusted earnings per share, per the cons

Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quart

Blue-chip growth stocks are all around us. Yet, finding the right fit for your particular portfolio is easier said than done.

The majority of leading global indices reached new highs in 2024, fueled by loose financial conditions and burgeoning enthusiasm for artificial intelligence (AI). In the U.S., this rally pushed the S&

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining i

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Demand is high for Eli Lilly's Zepbound, and the weight-loss drug market could reach $100 billion by the end of the decade. But one thing is getting in between some potential patients and this promisi

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.